Top of this page
Skip navigation, go straight to the content
At UCB,
we aspire to be the patient-preferred biotech leader.
To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.
Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.
In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success.
26 July 2018
Half-year report
UCB will publish its 2018 half-year financial report on 26 July. More details in due course.
IR events›
| Date | Event details |
|---|---|
| 26 July 2018 | 2018 half-year reportMore information in due course |
| 12 September 2018 | Morgan Stanley - Global Healthcare conference, New York City1/1 meetings |
| 13 September 2018 | Morgan Stanley - Global Healthcare conference, New York City1/1 meetings |
| 18 September 2018 | J.P. Morgan CEO conference call |
Latest News
- 14 Jun 2018 New Study Presented at the Annual European Congress of Rheumatology (EULAR 2018) Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy Journey
- 07 Jun 2018 New UCB Data Presented at the Annual European Congress of Rheumatology (EULAR 2018) Serves Key Patient Populations Including Ankylosing Spondylitis, Psoriatic Arthritis, and Women with Chronic Inflammatory Diseases
- 01 Jun 2018 UCB receives CHMP positive opinion for adjunctive use of BRIVIACT® as paediatric treatment for epilepsy patients
Outlook 2018
2018 revenue reporting to reach approximately
€ 4.5-4.6 billion
Recurring EBITDA [Operating profit adjusted for amortisation, depreciation, impairment charges, restructuring expenses and other exceptional income and expenses.] in the range of
€ 1.3-1.4 billion
Core earnings per share are therefore expected in the range of
€ 4.30-4.70
based on an average of
188 million shares outstanding
Contact UCB IR team
investor-relations@ucb.com or a specific team member:
- Antje Witte, VP Investor Relations
Tel: +32 2 559 9414
E-mail: Antje.Witte@ucb.com - Isabelle Ghellynck, Associate Director Investor Relations
Tel: +32 2 559 9588
E-mail: Isabelle.Ghellynck@ucb.com - Nathalie Deldime, Investor Relations Events Manager
Tel: +32 2 559 9291
E-mail: Nathalie.Deldime@ucb.com
UCB IR App
